Galapagos(GLPG) - 2025 Q4 - Annual Report

Financial Performance and Funding - The company has incurred significant operating losses since inception, with expectations of continued losses for the foreseeable future[22] - The company may require substantial additional funding, which may not be available on acceptable terms[22] - Shareholders may not receive dividends in the foreseeable future, limiting their return on investment to potential appreciation in share price[47] - The company may encounter difficulties in completing equity offerings due to limitations on preferential subscription rights for existing shareholders[50] Product Development and Regulatory Risks - The company is substantially dependent on the success of its only product candidate, GLPG3667, for future revenue generation[27] - The regulatory approval processes for product candidates are lengthy and unpredictable, which may affect commercial viability[29] - Clinical trials may reveal adverse events that could inhibit regulatory approvals or market acceptance of product candidates[35] - The company relies on third parties for conducting preclinical studies and clinical trials, which poses risks to obtaining regulatory approval[37] Collaboration and Competition - The company is heavily reliant on global collaboration agreements with Gilead for product development and commercialization, with no assurance of expected benefits[36] - The company faces significant competition in drug discovery and development, which could reduce commercial opportunities[34] Tax and Foreign Exchange Risks - The company may be classified as a passive foreign investment company (PFIC) for U.S. federal income tax purposes, which could lead to adverse tax consequences for certain U.S. holders[42] - The company believes it was not a controlled foreign corporation (CFC) for U.S. federal income tax purposes, but qualifying as a CFC could result in negative tax implications for certain U.S. holders[43] - The company may face significant foreign exchange risk, particularly with fluctuations between the U.S. dollar and the euro[44][46] Market and Shareholder Considerations - The market price of the American Depositary Shares (ADSs) could experience wide fluctuations, impacting shareholder value[45] - As a foreign private issuer, the company is exempt from certain U.S. securities laws, which may limit the information available to ADS holders[51] - The company may lose its foreign private issuer status in the future, potentially resulting in significant additional costs[52] Operational Challenges - The wind-down of cell therapy activities may not be completed in a timely manner or on favorable terms[23] - The ability to successfully implement business development strategies is critical for acquiring and commercializing product candidates[26]